Scholar Rock Removes Novo Nordisk Indiana Facility from FDA Application for Rare Muscle Weakness Drug
Scholar Rock announced it will remove Novo Nordisk's (formerly Catalent's) Indiana manufacturing facility from its FDA biologics license application for a treatment targeting a rare neuromuscular disease. The regulatory filing adjustment comes as the company seeks approval for its muscle weakness therapy.
